Development of Oral Small Molecule PCSK9 Antagonist

口服小分子PCSK9拮抗剂的研制

• 批准号: 9346559
• 负责人: Nabil A Elshourbagy
• 金额: $ 68.23万
• 依托单位: SHIFA BIOMEDICAL CORPORATION
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-15 至 2019-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9346559
• 关键词: Address; Advanced Development; Adverse effects; Animal Behavior; Animal Model; Binding; Binding Proteins; Bioavailable; Biochemistry; Biological Assay; Biological Availability; Blood; Cardiovascular Diseases; Cardiovascular system; Cause of Death; Cells; Cholesterol; Cholesterol Homeostasis; Clinical; Clinical Trials; Code; Coronary Arteriosclerosis; Cytochrome P450; Degradation Pathway; Development; Diet; Dose; Drug Compounding; Drug Kinetics; Education; Endoplasmic Reticulum; Ensure; Enzyme Precursors; Epidemic; Epidermal Growth Factor; Epidermal Growth Factor Receptor; Evaluation; Event; Exhibits; Familial Hypercholesterolemia; Fatty acid glycerol esters; Female; Formulation; Genes; Goals; Heart Diseases; Hemolysis; High Density Lipoproteins; High Fat Diet; In Vitro; Individual; Intervention; LDL Cholesterol Lipoproteins; Label; Lead; Link; Lipids; Liver; Low Density Lipoprotein Receptor; Low-Density Lipoproteins; Methods; Modeling; Molecular Chaperones; Morbidity - disease rate; Mus; Nonsense Mutation; Oral; Organ; Oryctolagus cuniculus; Patients; Peptide Hydrolases; Permeability; Pharmaceutical Preparations; Pharmacodynamics; Pharmacologic Substance; Pharmacotherapy; Phase; Plasma; Plasma Proteins; Population; Protein Precursors; Recombinants; Risk; Risk Factors; Route; Safety; Sequence Analysis; Source; Subtilisin Like Proprotein Convertases; Surface; Testing; Toxicology; Woman; Work; analog; base; cytotoxicity; drug candidate; drug market; efficacy testing; extracellular; gain of function mutation; high risk; histopathological examination; hypercholesterolemia; improved; in vivo; killings; lipid disorder; loss of function; loss of function mutation; male; men; mortality; nanocrystal; nanoformulation; nanomolar; novel; pre-clinical; premature; programs; screening; small molecule; subcutaneous; therapeutic target; trafficking; uptake; virtual

Project Summary/Abstract: The epidemic of cardiovascular disease (CVD) is a global phenomenon that remains the number one cause of death throughout the world, killing nearly 17.3 million people per year; a number that is expected to grow to 23.6 million by 2030. A high cholesterol level is well-known risk factors for heart disease. Although blood cholesterol can be lowered using a number of marketed drugs, of which statins are the leading drugs, only 38% of patients taking these drugs are achieving the low-density lipoprotein cholesterol goals set by the National Cholesterol Education Program (NCEP). Furthermore, patients with homozygous familial hypercholesterolemia who have markedly elevated cholesterol levels respond poorly to current drug therapy, and are at very high risk of premature cardiovascular disease. These and other patients will dramatically benefit from an aggressive treatment of hypercholesterolemia. The long-term goal of this work is to develop novel orally bioavailable drugs for cholesterol lowering. Our therapeutic target is the protease proprotein convertase subtilisin-like kexin type 9 (PCSK9). PCSK9 controls the degradation of the LDL receptor (LDLR) in the liver and thereby contributes to cholesterol homeostasis. PCSK9 is synthesized as a precursor protein that undergoes processing. Secreted PCSK9 binds to the LDL-receptor (LDLR) and chaperones it to the degradation pathway. To achieve our goal, we identified nanomolar orally active small molecule PCSK9/LDLR antagonists and demonstrated its efficacy in animal model. As part of this Phase-II proposal, we will undertake all the work required to characterize these compounds in multiple animal models for the proof of concept and conduct safety assessment in order to advance the lead compound toward IND-enabling studies and clinical trials.

项目摘要/摘要： 心血管疾病（CVD）的流行是一种全球现象，仍然是导致心血管疾病的首要原因。 全世界每年有近 1730 万人死亡；预计将增长到 到 2030 年，这一数字将达到 2360 万。众所周知，高胆固醇水平是心脏病的危险因素。虽然有血 可以使用许多市售药物来降低胆固醇，其中他汀类药物是主要药物，仅 服用这些药物的患者中有 38% 达到了 FDA 设定的低密度脂蛋白胆固醇目标 国家胆固醇教育计划 (NCEP)。此外，具有家族性纯合子的患者 胆固醇水平明显升高的高胆固醇血症对当前药物治疗反应不佳， 并且过早患心血管疾病的风险非常高。这些和其他患者将戏剧性地 受益于高胆固醇血症的积极治疗。这项工作的长期目标是发展 用于降低胆固醇的新型口服生物可利用药物。我们的治疗靶点是蛋白酶原蛋白 转化酶枯草杆菌蛋白酶样 kexin 9 型 (PCSK9)。 PCSK9 控制 LDL 受体 (LDLR) 的降解 肝脏，从而有助于胆固醇稳态。 PCSK9 是作为前体蛋白合成的 进行处理。分泌的 PCSK9 与 LDL 受体 (LDLR) 结合，并陪伴其与 降解途径。为了实现我们的目标，我们确定了纳摩尔口服活性小分子 PCSK9/LDLR 拮抗剂，并在动物模型中证明了其功效。作为第二阶段提案的一部分，我们将承诺 在多种动物模型中表征这些化合物所需的所有工作，以验证概念和 进行安全性评估，以推动先导化合物进行 IND 研究和临床 试验。